{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:11:55Z","timestamp":1789665115287,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,22]]},"DOI":"10.7759\/cureus.56685","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:50:08Z","timestamp":1711097408000},"source":"Crossref","is-referenced-by-count":4,"title":["Late-Stage Ovarian Cancer With Systemic Multiple Metastases Marked Shrinkage Using a Combination of Wilms' Tumor Antigen 1 (WT1) Dendritic Cell Vaccine, Natural Killer (NK) Cell Therapy, and Nivolumab"],"prefix":"10.7759","author":[{"given":"Hisashi","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Karube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly C","year":"2020","unstructured":"Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020, 2:zcaa002. 10.1093\/narcan\/zcaa002","journal-title":"NAR Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70985-8","article-title":"Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited","volume":"8","author":"Gabrilovich DI","year":"2007","unstructured":"Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol. 2007, 8:2-3. 10.1016\/S1470-2045(06)70985-8","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever MA","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, et al.. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009, 15:5323-37. 10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00049480","article-title":"Role of natural killer cells in control of cancer metastasis","volume":"1","author":"Hanna N","year":"1982","unstructured":"Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev. 1982, 1:45-64. 10.1007\/BF00049480","journal-title":"Cancer Metastasis Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp194","article-title":"WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy","volume":"40","author":"Sugiyama H","year":"2010","unstructured":"Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010, 40:377-87. 10.1093\/jjco\/hyp194","journal-title":"Jpn J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48412","article-title":"Radioimmunotherapy with WT1 dendritic cell vaccine for end-stage lung adenocarcinoma markedly shrinks tumors","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R, Zhao F. Radioimmunotherapy with WT1 dendritic cell vaccine for end-stage lung adenocarcinoma markedly shrinks tumors. Cureus. 2023, 15:e48412. 10.7759\/cureus.48412","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49221","article-title":"Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms\u2019 tumor 1 (WT1) dendritic cell vaccine therapy","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms\u2019 tumor 1 (WT1) dendritic cell vaccine therapy. Cureus. 2023, 15:e49221. 10.7759\/cureus.49221","journal-title":"Cureus"},{"key":"ref8","article-title":"Natural killer cell activity and head and neck cancer: a clinical assessment","volume":"77","author":"Schantz SP","year":"1986","unstructured":"Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986, 77:869-75.","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald T","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020, 21:835-47. 10.1038\/s41590-020-0728-z","journal-title":"Nat Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki N","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020, 19:200-18. 10.1038\/s41573-019-0052-1","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/7403","article-title":"Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo","volume":"5","author":"Fernandez NC","year":"1999","unstructured":"Fernandez NC, Lozier A, Flament C, et al.. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999, 5:405-11. 10.1038\/7403","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20897","article-title":"Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands","volume":"1","author":"Munich S","year":"2012","unstructured":"Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology. 2012, 1:1074-83. 10.4161\/onci.20897","journal-title":"Oncoimmunology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658698","article-title":"Natural killer cell-derived extracellular vesicles: novel players in cancer immunotherapy","volume":"12","author":"Wu F","year":"2021","unstructured":"Wu F, Xie M, Hun M, et al.. Natural killer cell-derived extracellular vesicles: novel players in cancer immunotherapy. Front Immunol. 2021, 12:10.3389\/fimmu.2021.658698","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nri1549","article-title":"Close encounters of different kinds: dendritic cells and NK cells take centre stage","volume":"5","author":"Degli-Esposti MA","year":"2005","unstructured":"Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol. 2005, 5:112-24. 10.1038\/nri1549","journal-title":"Nat Rev Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47320","article-title":"WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer. Cureus. 2023, 15:e47320. 10.7759\/cureus.47320","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01999","article-title":"NK cell dysfunction and checkpoint immunotherapy","volume":"10","author":"Bi J","year":"2019","unstructured":"Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol. 2019, 10:1999. 10.3389\/fimmu.2019.01999","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan M","year":"2020","unstructured":"Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020, 11:167. 10.3389\/fimmu.2020.00167","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 blockade enhances anti-tumor efficacy of NK cells","volume":"7","author":"Oyer JL","year":"2018","unstructured":"Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018, 7:e1509819. 10.1080\/2162402X.2018.1509819","journal-title":"Oncoimmunology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466018","article-title":"Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types","volume":"7","author":"Hicks KC","year":"2018","unstructured":"Hicks KC, Fantini M, Donahue RN, et al.. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. Oncoimmunology. 2018, 7:e1466018. 10.1080\/2162402X.2018.1466018","journal-title":"Oncoimmunology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells","volume":"9","author":"Juli\u00e1 EP","year":"2018","unstructured":"Juli\u00e1 EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells. Front Immunol. 2018, 9:2140. 10.3389\/fimmu.2018.02140","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239260-late-stage-ovarian-cancer-with-systemic-multiple-metastases-marked-shrinkage-using-a-combination-of-wilms-tumor-antigen-1-wt1-dendritic-cell-vaccine-natural-killer-nk-cell-therapy-and-nivolumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:50:16Z","timestamp":1711097416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239260-late-stage-ovarian-cancer-with-systemic-multiple-metastases-marked-shrinkage-using-a-combination-of-wilms-tumor-antigen-1-wt1-dendritic-cell-vaccine-natural-killer-nk-cell-therapy-and-nivolumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.56685","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}